Matt Schenauer

Matt Schenauer has extensive experience in the biotechnology and pharmaceutical industries, serving in various leadership roles focused on analytical development and quality control. At Inhibrx, Inc., Matt held the position of Senior Director ADQC and Director of Analytical Development and Quality Control from July 2021 to January 2024. Prior experience includes roles such as Group Leader and Principal Scientist I at Gilead Sciences, where Matt contributed from January 2017 to June 2021, and a Scientist position at Genentech. Additionally, Matt worked as a Bioanalytical Scientist at Allergan and as a Postdoctoral Fellow at Amgen in Analytical and Formulation Sciences. An MBA in Digital Transformation was obtained from the Paul Merage School of Business at the University of California, Irvine, and a Doctorate in Biochemistry and Molecular Biology was earned from the University of California, Davis.